Sonnet Biotherapeutics Holdings Inc (SONN)

$0.85

-0.01

(-1.17%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $0.85
    $0.88
    $0.85
    downward going graph

    0.0%

    Downside

    Day's Volatility :3.41%

    Upside

    3.41%

    downward going graph
  • $0.83
    $10.09
    $0.85
    downward going graph

    2.94%

    Downside

    52 Weeks Volatility :91.82%

    Upside

    91.58%

    downward going graph

Returns

PeriodSonnet Biotherapeutics Holdings IncIndex (Russel 2000)
3 Months
-49.85%
0.0%
6 Months
-35.61%
0.0%
1 Year
-89.39%
0.0%
3 Years
-99.75%
-19.4%

Highlights

Market Capitalization
4.5M
Book Value
$0.98
Earnings Per Share (EPS)
2.81
PE Ratio
0.31
Wall Street Target Price
27.0
Profit Margin
0.0%
Operating Margin TTM
-13655.51%
Return On Assets TTM
-82.35%
Return On Equity TTM
-200.09%
Revenue TTM
92.7K
Revenue Per Share TTM
0.03
Quarterly Revenue Growth YOY
-50.0%
Gross Profit TTM
-21.1M
EBITDA
-12.7M
Diluted Eps TTM
2.81
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.14
EPS Estimate Next Year
-2.52
EPS Estimate Current Quarter
0.13
EPS Estimate Next Quarter
-0.48

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Sonnet Biotherapeutics Holdings Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 3076.47%

Current $0.85
Target $27.00

Technicals Summary

Sell

Neutral

Buy

Sonnet Biotherapeutics Holdings Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Sonnet Biotherapeutics Holdings Inc
Sonnet Biotherapeutics Holdings Inc
-18.27%
-35.61%
-89.39%
-99.75%
-99.96%
Moderna, Inc.
Moderna, Inc.
-9.87%
21.5%
-2.91%
-60.58%
762.21%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
1.84%
12.81%
47.11%
81.12%
258.69%
Novo Nordisk A/s
Novo Nordisk A/s
-6.7%
24.69%
59.95%
200.63%
443.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.28%
11.69%
35.86%
150.1%
182.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Sonnet Biotherapeutics Holdings Inc
Sonnet Biotherapeutics Holdings Inc
0.31
0.31
NA
-2.14
-2.0
-0.82
NA
0.98
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.53
31.53
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.49
45.49
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.66
31.66
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Sonnet Biotherapeutics Holdings Inc
Sonnet Biotherapeutics Holdings Inc
Buy
$4.5M
-99.96%
0.31
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.5B
762.21%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.5B
258.69%
31.53
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$589.9B
443.55%
45.49
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
182.38%
31.66
39.46%

Insights on Sonnet Biotherapeutics Holdings Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 37.25K → 18.62K (in $), with an average decrease of 50.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 5 quarters, -5.67M → 365.42K (in $), with an average increase of 171.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 59.9% return, outperforming this stock by 149.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 200.6% return, outperforming this stock by 300.4%

Institutional Holdings

  • Susquehanna International Group, LLP

    1.11%
  • Vanguard Group Inc

    0.47%
  • Virtu Financial LLC

    0.35%
  • Tower Research Capital LLC

    0.09%
  • BlackRock Inc

    0.02%

Company Information

sonnet biotherapeutics is an early stage company developing a pipeline of bifunctional therapies that attack immune-modulating targets to control cancer cells. sonnet biotherapeutics is utilizing a platform approach to develop a library of cancer-fighting immunotherapies. sonnet is based in cranbury, new jersey. sonnet mission: sonnet biotherapeutics is a platform enabled proof-of-concept engine created to generate immuno-oncology candidates and develop them into phase ii assets. we are leveraging a unique ip driven platform: ● single chain platform with pk enhancement ● selectively targeting tumors and their micro-environment ● validated targets only ● dual targeting can create synergies

Organization
Sonnet Biotherapeutics Holdings Inc
Employees
12
CEO
Dr. Pankaj Mohan Ph.D.
Industry
Consumer Services

FAQs